Cytokinetics, Inc. (NASDAQ: CYTK) Starts Presentation at 29th Annual ROTH Conference
Cytokinetics (NASDAQ: CYTK) is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal troponin activator (FSTA). Tirasemtiv is the subject of VITALITY-ALS, an international phase 3 clinical trial in patients with ALS. Tirasemtiv has been granted FDA orphan drug designation and fast track status, as well as orphan medicinal product designation by the EMA. Cytokinetics is preparing for the potential commercialization of tirasemtiv in North America…
